Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort

Pokphazz Christjaroon, Ali Abid, Orli Wargon, Paul Weller, Artiene Tatian
Australasian Journal of Dermatology · Wiley · 2026-10-17 · DOI: 10.1111/ajd.70221

Abstract

ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris ( n = 16) or pemphigus foliaceus ( n = 8) received rituximab as part of routine care; median follow‐up from first infusion was 24.9 months. Disease control was documented in all patients and complete remission in 20 (83%), of whom half subsequently relapsed despite most receiving more than one cycle. Adverse events occurred in eight patients (33%), predominantly mild infusion‐related reactions, with one fatal pneumonia. These real‐world data support planned maintenance after remission rather than single‐course rescue use, and prospective multicentre study with standardised severity scoring.

Read at publisher →

Similar articles